ABOUT THE CONFERENCE ORGANIZERS

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for cancer research and training. As the nation’s leading federal agency for cancer research, NCI has 30 divisions, offices, and centers that work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Their work ranges from cutting-edge research on cancer causes, treatment, and prevention; to training the next generation of cancer researchers; to funding and supporting the nation’s vast network of scientists and cancer research institutions; to informing and educating the American public and the world about cancer.

The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individual European hospitals and can be best accomplished through the multidisciplinary multinational efforts of basic scientists and clinicians.

The goal of the EORTC is to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery, and/or radiotherapy that are already in use. The EORTC also contributes to the development of new drugs and other innovative approaches in partnership with the pharmaceutical industry. This is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. In this way, the EORTC facilitates the passage of experimental discoveries into state-of-the-art treatments.

Scientific Committee Cochairs

Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts (AACR)*
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)*
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain (EORTC)* 

Organizing Committee Cochairs

Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut (AACR)*
James H. Doroshow, National Cancer Institute, Bethesda, Maryland (NCI)*
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)*

Scientific Committee Members

Rosemarie Aurigemma, NIH-NCI, Rockville, Maryland
Nilofer S. Azad, Johns Hopkins University, Baltimore, Maryland*
Udai Banerji, The Institute of Cancer Research, London, United Kingdom
Bristi Basu, University of Cambridge, Cambridge, United Kingdom
Philippe L. Bedard, University Health Network, Toronto, Ontario, Canada
Johanna Bendell, Pfizer, Bothell, Washington
Alice P. Chen, National Cancer Institute, Bethesda, Maryland
Raffaele Colombo, Zymeworks, Inc., Vancouver, British Columbia, Canada
Natalie Cook, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
Benjamin F. Cravatt, The Scripps Research Institute, San Diego, California
Giuseppe Curigliano, European Institute of Oncology, Milan, Italy
E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, Netherlands*
Jaydira Del Rivero, National Cancer Institute, Bethesda, Maryland*
James H. Doroshow, NCI Division of Cancer Treatment and Diagnosis, Bethesda, Maryland
Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, New York*
Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, Texas
Anna Farago, Amgen Oncology, Thousand Oaks, California
Elena Garralda, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain
Steven D. Gore, National Institutes of Health, Baltimore, Maryland
Lyndsay N. Harris, National Cancer Institute, Rockville, Maryland
Sara A. Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington
S. Percy Ivy, National Cancer Institute, Bethesda, Maryland
Katrina L. Jackson, C4 Therapeutics, Watertown, Massachusetts
Peng Jiang, National Cancer Institute, Bethesda, Maryland
Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, Tennessee 
Stephen Kelsey, Revolution Medicines, Redwood City, California
Jung-Min Lee, National Cancer Institute, Bethesda, Maryland
Christophe Massard, Gustave Roussy, Rennes, France
Victor Moreno, START Madrid, Madrid, Spain
Ralph E. Parchment, NCI-Frederick/Leidos Biomedical Research, Inc., Frederick, Maryland
Lilli Petruzzelli, Genentech, Inc., San Francisco, California
Yves G. Pommier, National Cancer Institute, Bethesda, Maryland
Victoria Sanchez, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain
John Schneekloth, National Cancer Institute, Frederick, Maryland
Patrick Schöffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Alison Schram, Memorial Sloan Kettering Cancer Center, Scarsdale, New York
Lesley K. Seymour, Queen’s University, Kingston, Ontario, Canada
Alexander Spira, Virginia Cancer Specialists, Herndon, Virginia
Neeltje Steeghs, Netherlands Cancer Institute, Amsterdam, Netherlands
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, Tennessee
Stefan N. Symeonides, University of Edinburgh, Edinburgh, United Kingdom*
Beverly A. Teicher, National Cancer Institute, Rockville, Maryland
Craig Thomas, National Center for Advancing Translational Sciences, Rockville, Maryland*
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Samra Turajlic, The Francis Crick Institute, London, United Kingdom
Andreas S. Varkaris, MGH/Harvard Medical School, Boston, Massachusetts
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom
Jing Wu, National Cancer Institute, Bethesda, Maryland
Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts
Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa City, Japan

* – denotes Executive Committee Member